Stay updated with breaking news from Enz Alone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ESSA Pharma Inc. announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide at the 30th Annual Prostate Cancer...
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently...
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently...
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently...